Murine model of chronic L. (Viannia) panamensis infection: Role of IL-13 in disease

European Journal of Immunology

Volumn 40, Issue 10, 2010, Pages 2816-2829

  Castilho, Tiago M ^a   Goldsmith Pestana, Karen ^a   Lozano, Caterin ^b   Valderrama, Liliana ^b   Saravia, Nancy G ^b   McMahon Pratt, Diane ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CENTRO INTERNACIONAL DE ENTRENAMIENTO E INVESTIGACIONES MÉDICAS CIDEIM   (Colombia)

Author keywords

Chronic infection; IL 13; Leishmania (Viannia); Leishmaniasis; Murine model

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 4 RECEPTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AMASTIGOTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHRONIC DISEASE; DISEASE CONTROL; FEMALE; HEALING; HUMAN; IMMUNE RESPONSE; LEISHMANIA PANAMENSIS; LEISHMANIASIS; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PARASITE CONTROL; PATHOLOGY; PERSISTENT INFECTION; PRIORITY JOURNAL; RECURRENT DISEASE; SCID MOUSE; TH1 CELL; TH2 CELL;

ADOLESCENT; ADULT; ANIMALS; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-13; LEISHMANIA; LEISHMANIASIS, CUTANEOUS; MALE; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MIDDLE AGED; RECEPTORS, INTERLEUKIN-4; TH1 CELLS; TH2 CELLS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 77957128626     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201040384     Document Type: Article

References (68)

1. Murray, H. W., Flanders, K. C., Donaldson, D. D., Sypek, J. P., Gotwals, P. J., Liu, J. and Ma, X., Antagonizing deactivating cytokines to enhance host defense and chemotherapy in experimental visceral leishmaniasis. Infect. Immun. 2005. 73: 3903-3911.
2. WHO, Magnitude of the Problem 2009 http://www.who.int/leishmaniasis/ burden/magnitude/burden-magnitude/en/index.html.
3. Grimaldi, G., Jr. , Tesh, R. B. and McMahon-Pratt, D., A review of the geographic distribution and epidemiology of leishmaniasis in the New World. Am. J. Trop. Med. Hyg. 1989. 41: 687-725.
4. Pirmez, C., Yamamura, M., Uyemura, K., Paes-Oliveira, M., Conceicao- Silva, F. and Modlin, R. L., Cytokine patterns in the pathogenesis of human leishmaniasis. J. Clin. Invest. 1993. 91: 1390-1395.
5. Bosque, F., Saravia, N. G., Valderrama, L. and Milon, G., Distinct innate and acquired immune responses to Leishmania in putative susceptible and resistant human populations endemically exposed to L. (Viannia) panamensis infection. Scand. J. Immunol. 2000. 51: 533-541.
6. Bourreau, E., Prevot, G., Gardon, J., Pradinaud, R. and Launois, P., High intralesional interleukin-10 messenger RNA expression in localized cutaneous leishmaniasis is associated with unresponsiveness to treatment. J. Infect. Dis. 2001. 184: 1628-1630.
7. Gollob, K. J., Antonelli, L. R., Faria, D. R., Keesen, T. S. and Dutra, W. O., Immunoregulatory mechanisms and CD4-CD8- (double negative) T cell subpopulations in human cutaneous leishmaniasis: a balancing act between protection and pathology. Int. Immunopharmacol. 2008. 8: 1338-1343.
8. Salhi, A., Rodrigues, V., Jr., Santoro, F., Dessein, H., Romano, A., Castellano, L. R., Sertorio, M. et al., Immunological and genetic evidence for a crucial role of IL-10 in cutaneous lesions in humans infected with Leishmania braziliensis. J. Immunol. 2008. 180: 6139-6148.
9. Bacellar, O., Lessa, H., Schriefer, A., Machado, P., Ribeiro de Jesus, A., Dutra, W. O., Gollob, K. J. and Carvalho, E. M., Up-regulation of Th1-type responses in mucosal leishmaniasis patients. Infect. Immun. 2002. 70: 6734-6740.
10. Bacellar, O., Faria, D., Nascimento, M., Cardoso, T. M., Gollob, K. J., Dutra, W. O., Scott, P. and Carvalho, E. M., Interleukin 17 production among patients with American cutaneous leishmaniasis. J. Infect. Dis. 2009. 200: 75-78.
11. Bourreau, E., Prevot, G., Pradinaud, R. and Launois, P., Interleukin (IL)-13 is the predominant Th2 cytokine in localized cutaneous leishmaniasis lesions and renders specific CD4+T cells unresponsive to IL-12. J. Infect. Dis. 2001. 183: 953-959.
12. Maurer-Cecchini, A., Decuypere, S., Chappuis, F., Alexandrenne, C., De Doncker, S., Boelaert, M., Dujardin, J. C. et al., Immunological determinants of clinical outcome in Peruvian patients with tegumentary leishmaniasis treated with pentavalent antimonials. Infect. Immun. 2009. 77: 2022-2029.
13. Samuelson, J., Lerner, E., Tesh, R. and Titus, R., A mouse model of Leishmania braziliensis infection produced by coinjection with sand fly saliva. J. Exp. Med. 1991. 173: 49-54.
14. de Moura, T. R., Novais, F. O., Oliveira, F., Clarencio, J., Noronha, A., Barral, A., Brodskyn, C. and de Oliveira, C. I., Toward a novel experimental model of infection to study American cutaneous leishmaniasis caused by Leishmania braziliensis. Infect. Immun. 2005. 73: 5827-5834.
15. Rocha, F. J., Schleicher, U., Mattner, J., Alber, G. and Bogdan, C., Cytokines, signaling pathways, and effector molecules required for the control of Leishmania (Viannia) braziliensis in mice. Infect. Immun. 2007. 75: 3823-3832.
16. Vargas-Inchaustegui, D. A., Tai, W., Xin, L., Hogg, A. E., Corry, D. B. and Soong, L., Distinct roles for MyD88 and Toll-like receptor 2 during Leishmania braziliensis infection in mice. Infect. Immun. 2009. 77: 2948-2956.
17. Neal, R. A. and Hale, C., A comparative study of susceptibility of inbred and outbred mouse strains compared with hamsters to infection with New World cutaneous leishmaniases. Parasitology 1983. 87: 7-13. (Pubitemid 13042318)
18. Eperon, S. and McMahon-Pratt, D., Extracellular amastigote-like forms of Leishmania panamensis and L. braziliensis II. Stage- and sspecies-specific monoclonal antibodies. J. Protozool. 1989. 36: 510-518.
19. Walters, L. L., Chaplin, G. L., Modi, G. B. and Tesh, R. B., Ultrastructural biology of Leishmania (Viannia) panamensis (5Leishmania braziliensis panamensis) in Lutzomyia gomezi (Diptera: Psychodidae): a natural host-parasite association. Am. J. Trop. Med. Hyg. 1989. 40: 19-39.
20. Ahmed, S., Colmenares, M., Soong, L., Goldsmith-Pestana, K., Munstermann, L., Molina, R. and McMahon-Pratt, D., Intradermal infection model for pathogenesis and vaccine studies of murine visceral leishmaniasis. Infect. Immun. 2003. 71: 401-410.
21. Colmenares, M., Constant, S. L., Kima, P. E. and McMahon-Pratt, D., Leishmania pifanoi pathogenesis: selective lack of a local cutaneous response in the absence of circulating antibody. Infect. Immun. 2002. 70: 6597-6605.
22. Kima, P. E., Constant, S. L., Hannum, L., Colmenares, M., Lee, K. S., Haberman, A. M., Shlomchik, M. J. and McMahon-Pratt, D., Internalization of Leishmania mexicana complex amastigotes via the Fc receptor is required to sustain infection in murine cutaneous leishmaniasis. J. Exp. Med. 2000. 191: 1063-1068.
23. de Oliveira Camera, P., Junger, J., do Espirito Santo Silva Pires, F., Mattos, M., Oliveira-Neto, M. P., Fernandes, O. and Pirmez, C., Haematogenous dissemination of Leishmania (Viannia) braziliensis in human American tegumentary leishmaniasis. Trans. R Soc. Trop. Med. Hyg. 2006. 100: 1112-1117.
24. Fagundes, A., Marzochi, M. C., Fernandes, O., Perez, M. A., Schubach, A. O., Schubach, T. M., Amendoeira, M. R. et al., First encounter of subclinical human Leishmania (Viannia) infection in State of Rio Grande do Sul, Brazil. Mem. Inst. Oswaldo Cruz 2007. 102: 1003-1005.
25. Figueroa, R. A., Lozano, L. E., Romero, I. C., Cardona, M. T., Prager, M., Pacheco, R., Diaz, Y. R. et al., Detection of Leishmania in unaffected mucosal tissues of patients with cutaneous leishmaniasis caused by Leishmania (Viannia) species. J. Infect. Dis. 2009. 200: 638-646.
26. Saravia, N. G., Holguin, A. F., McMahon-Pratt, D. and D'Alessandro, A., Mucocutaneous leishmaniasis in Colombia: Leishmania braziliensis subspecies diversity. Am. J. Trop. Med. Hyg. 1985. 34: 714-720.
27. Bomfim, G., Andrade, B. B., Santos, S., Clarencio, J., Barral-Netto, M. and Barral, A., Cellular analysis of cutaneous leishmaniasis lymphadenopathy: insights into the early phases of human disease. Am. J. Trop. Med. Hyg. 2007. 77: 854-859.
28. Deak, E., Jayakumar, A., Cho, K. W., Goldsmith-Pestana, K., Dondji, B., Lambris, J. D. and McMahon-Pratt, D., Murine visceral leishmaniasis: IgM and polyclonal B-cell activation lead to disease exacerbation. Eur. J. Immunol. 2010. 40: 1355-1368.
29. Hsu, A. C. and Scott, P., Leishmania mexicana infection induces impaired lymph node expansion and Th1 cell differentiation despite normal T cell proliferation. J. Immunol. 2007. 179: 8200-8207.
30. Smelt, S. C., Cotterell, S. E., Engwerda, C. R. and Kaye, P. M., B cell-deficient mice are highly resistant to Leishmania donovani infection, but develop neutrophil-mediated tissue pathology. J. Immunol. 2000. 164: 3681-3688.
31. Ronet, C., Voigt, H., Himmelrich, H., Doucey, M. A., Hauyon-La Torre, Y., Revaz-Breton, M. et al., Leishmania major-specific B cells are necessary for Th2 cell development and susceptibility to L. major LV39 in BALB/c mice. J. Immunol. 2008. 180: 4825-4835.
32. Matthews, D. J., Emson, C. L., McKenzie, G. J., Jolin, H. E., Blackwell, J. M. and McKenzie, A. N., IL-13 is a susceptibility factor for Leishmania major infection. J. Immunol. 2000. 164: 1458-1462.
33. Alexander, J., Brombacher, F., McGachy, H. A., McKenzie, A. N., Walker, W. and Carter, K. C., An essential role for IL-13 in maintaining a non-healing response following Leishmania mexicana infection. Eur. J. Immunol. 2002. 32: 2923-2933.
34. Radwanska, M., Cutler, A. J., Hoving, J. C., Magez, S., Holscher, C., Bohms, A., Arendse, B. et al., Deletion of IL-4Ralpha on CD4 T cells renders BALB/c mice resistant to Leishmania major infection. PLoS Pathog. 2007. 3: e68.
35. Silveira, F. T., Lainson, R., De Castro Gomes, C. M., Laurenti, M. D. and Corbett, C. E., Immunopathogenic competences of Leishmania (V.) braziliensis and L. (L.) amazonensis in American cutaneous leishmaniasis. Parasite Immunol. 2009. 31: 423-431.
36. Laskay, T., Mariam, H. G., Berhane, T. Y., Fehniger, T. E. and Kiessling, R., Immune reactivity to fractionated Leishmania aethiopica antigens during active human infection. J. Clin. Microbiol. 1991. 29: 757-763.
37. Ajdary, S., Alimohammadian, M. H., Eslami, M. B., Kemp, K. and Kharazmi, A., Comparison of the immune profile of nonhealing cutaneous leishmaniasis patients with those with active lesions and those who have recovered from infection. Infect. Immun. 2000. 68: 1760-1764.
38. el-Hassan, A. M. and Zijlstra, E. E., Leishmaniasis in Sudan: cutaneous leishmaniasis. Trans. R Soc. Trop. Med. Hyg. 2001. 95: S1-S17.
39. Melby, P. C., Andrade-Narvaez, F. J., Darnell, B. J., Valencia-Pacheco, G., Tryon, V. V. and Palomo-Cetina, A., Increased expression of proinflammatory cytokines in chronic lesions of human cutaneous leishmaniasis. Infect. Immun. 1994. 62: 837-842.
40. Saravia, N. G., Weigle, K., Segura, I., Giannini, S. H., Pacheco, R., Labrada, L. A. and Goncalves, A., Recurrent lesions in human Leishmania braziliensis infection - reactivation or reinfection? Lancet 1990. 336: 398-402.
41. Nugent, P. G., Karsani, S. A., Wait, R., Tempero, J. and Smith, D. F., Proteomic analysis of Leishmania mexicana differentiation. Mol. Biochem. Parasitol. 2004. 136: 51-62.
42. Courret, N., Frehel, C., Prina, E., Lang, T. and Antoine, J. C., Kinetics of the intracellular differentiation of Leishmania amazonensis and internalization of host MHC molecules by the intermediate parasite stages. Parasitology 2001. 122: 263-279.
43. Gutierrez, Y., Salinas, G. H., Palma, G., Valderrama, L., Santrich, C. V. and Saravia, N. G., Correlation between histopathology, immune response, clinical presentation, and evolution in Leishmania braziliensis infection. Am. J. Trop. Med. Hyg. 1991. 45: 281-289.
44. Barral, A., Barral-Netto, M., Almeida, R., de Jesus, A. R., Grimaldi Junior, G., Netto, E. M. et al., Lymphadenopathy associated with Leishmania braziliensis cutaneous infection. Am. J. Trop. Med. Hyg. 1992. 47: 587-592.
45. Barral, A., Guerreiro, J., Bomfim, G., Correia, D., Barral-Netto, M. and Carvalho, E. M., Lymphadenopathy as the first sign of human cutaneous infection by Leishmania braziliensis. Am. J. Trop. Med. Hyg. 1995. 53: 256-259.
46. Saravia, N. G., Valderrama, L., Labrada, M., Holguin, A. F., Navas, C., Palma, G. and Weigle, K. A., The relationship of Leishmania braziliensis subspecies and immune response to disease expression in New World leishmaniasis. J. Infect. Dis. 1989. 159: 725-735.
47. Guarin, N., Palma, G. I., Pirmez, C., Valderrama, L., Tovar, R. and Saravia, N. G., Comparative immunohistological analysis of the Montenegro skin test reaction in asymptomatic infection and in acute and chronic cutaneous leishmaniasis. Biomedica 2006. 26: 38-48.
48. O'Neil, C. E., Labrada, M. and Saravia, N. G., Leishmania (Viannia) panamensis-specific IgE and IgA antibodies in relation to expression of human tegumentary leishmaniasis. Am. J. Trop. Med. Hyg. 1993. 49: 181-188.
49. Palma, G. I. and Saravia, N. G., In situ characterization of the human host response to Leishmania panamensis. Am. J. Dermatopathol. 1997. 19: 585-590.
50. Trujillo, C. M., Robledo, S. M., Franco, J. L., Velez, I. D., Erb, K. J. and Patino, P. J., Endemically exposed asymptomatic individuals show no increase in the specific Leishmania (Viannia) panamensis-Th1 immune response in comparison to patients with localized cutaneous leishmaniasis. Parasite Immunol. 2002. 24: 455-462.
51. Diaz, Y. R., Rojas, R., Valderrama, L. and Saravia, N. G., T-bet, GATA-3, and Foxp3 expression and Th1/Th2 cytokine production in the clinical outcome of human infection with Leishmania (Viannia) species. J. Infect. Dis. 2010. 202: 406-415.
52. Mendonca, M. G., de Brito, M. E., Rodrigues, E. H., Bandeira, V., Jardim, M. L. and Abath, F. G., Persistence of leishmania parasites in scars after clinical cure of American cutaneous leishmaniasis: is there a sterile cure? J. Infect. Dis. 2004. 189: 1018-1023.
53. Coutinho, S. G., Pirmez, C. and Da-Cruz, A. M., Parasitological and immunological follow-up of American tegumentary leishmaniasis patients. Trans. R Soc. Trop. Med. Hyg. 2002. 96: S173-S178.
54. Schubach, A., Marzochi, M. C., Cuzzi-Maya, T., Oliveira, A. V., Araujo, M. L., Oliveira, A. L., Pacheco, R. S. et al., Cutaneous scars in American tegumentary leishmaniasis patients: a site of Leishmania (Viannia) braziliensis persistence and viability eleven years after antimonial therapy and clinical cure. Am. J. Trop. Med. Hyg. 1998. 58: 824-827.
55. Bourreau, E., Ronet, C., Darsissac, E., Lise, M. C., Marie, D. S., Clity, E., Tacchini-Cottier, F. et al., In leishmaniasis due to Leishmania guyanensis infection, distinct intralesional interleukin-10 and Foxp3 mRNA expression are associated with unresponsiveness to treatment. J. Infect. Dis. 2009. 199: 576-579.
56. Sosa, M. R., Rosas, L. E., McKenzie, A. N. and Satoskar, A. R., IL-13 gene-deficient mice are susceptible to cutaneous L. mexicana infection. Eur. J. Immunol. 2001. 31: 3255-3260.
57. Wills-Karp, M. and Finkelman, F. D., Untangling the complex web of IL-4- and IL-13-mediated signaling pathways. Sci. Signal. 2008. 1: pe55.
58. Holscher, C., Arendse, B., Schwegmann, A., Myburgh, E. and Brombacher, F., Impairment of alternative macrophage activation delays cutaneous leishmaniasis in nonhealing BALB/c mice. J. Immunol. 2006. 176: 1115-1121. (Pubitemid 43099713)
59. de Souza-Neto, S. M., Carneiro, C. M., Vieira, L. Q. and Afonso, L. C., Leishmania braziliensis: partial control of experimental infection by interleukin-12 p40 deficient mice. Mem. Inst. Oswaldo Cruz 2004. 99: 289-294.
60. Lopez Kostka, S., Dinges, S., Griewank, K., Iwakura, Y., Udey, M. C. and von Stebut, E., IL-17 promotes progression of cutaneous leishmaniasis in susceptible mice. J. Immunol. 2009. 182: 3039-3046.
61. Vargas-Inchaustegui, D. A., Xin, L. and Soong, L., Leishmania braziliensis infection induces dendritic cell activation, ISG15 transcription, and the generation of protective immune responses. J. Immunol. 2008. 180: 7537-7545.
62. Newcomb, D. C., Zhou, W., Moore, M. L., Goleniewska, K., Hershey, G. K., Kolls, J. K. and Peebles, R. S., Jr., A functional IL-13 receptor is expressed on polarized murine CD4+Th17 cells and IL-13 signaling attenuates Th17 cytokine production. J. Immunol. 2009. 182: 5317-5321.
63. McCusker, C. T., Wang, Y., Shan, J., Kinyanjui, M. W., Villeneuve, A., Michael, H. and Fixman, E. D., Inhibition of experimental allergic airways disease by local application of a cell-penetrating dominant-negative STAT-6 peptide. J. Immunol. 2007. 179: 2556-2564.
64. Castilho, T. M., Camargo, L. M., McMahon-Pratt, D., Shaw, J. J. and Floeter-Winter, L. M., A real-time polymerase chain reaction assay for the identification and quantification of American Leishmania species on the basis of glucose-6-phosphate dehydrogenase. Am. J. Trop. Med. Hyg. 2008. 78: 122-132.
65. McMahon-Pratt, D., Bennett, E. and David, J. R., Monoclonal antibodies that distinguish subspecies of Leishmania braziliensis. J. Immunol. 1982. 129: 926-927.
66. Weigle, K. A., Valderrama, L., Arias, A. L., Santrich, C. and Saravia, N. G., Leishmanin skin test standardization and evaluation of safety, dose, storage, longevity of reaction and sensitization. Am. J. Trop. Med. Hyg. 1991. 44: 260-271.
67. Weigle, K. A., Santrich, C., Martinez, F., Valderrama, L. and Saravia, N. G., Epidemiology of cutaneous leishmaniasis in Colombia: a longitudinal study of the natural history, prevalence, and incidence of infection and clinical manifestations. J. Infect. Dis. 1993. 168: 699-708.
68. Mohrs, M., Holscher, C. and Brombacher, F., Interleukin-4 receptor alpha-deficient BALB/c mice show an unimpaired T helper 2 polarization in response to Leishmania major infection. Infect. Immun. 2000. 68: 1773-1780.